COVID-19 has changed the way we live, work and interact with others, like no other disease. In spite of intensive global and national efforts for almost two years, the pandemic continues to spread unabated and has taken a heavy toll on human health and economy.

As a research oriented pharmaceutical company, Ultratech has remained committed to fulfilling its responsibility towards developing life saving drugs.

Ultratech’s R&D unit has been working relentlessly during COVID times and have been successful in developing the following Anti-viral therapeutics against SARS-COV-2:

Anti-viral APIs

  • Favipiravir
  • Molnupiravir
  • Nirmatrelvir
  • Umifenovir Hydrochloride Monohydrate

Anti-viral FDFs

  • Remdesivir Pressurized Metered Dose Inhalation
  • Remdesivir Dry Powder for Inhalation
  • Molnupiravir Capsules
  • Umifenovir Capsules
  • Umifenovir Oral Suspension
These API molecules and Finished dosage forms shall be provided in LMICs and other Countries after their regulatory approvals.